AR067507A1 - Estratrienos 8-beta-sustituidos como estrogeno de accion selectiva - Google Patents
Estratrienos 8-beta-sustituidos como estrogeno de accion selectivaInfo
- Publication number
- AR067507A1 AR067507A1 ARP080102978A ARP080102978A AR067507A1 AR 067507 A1 AR067507 A1 AR 067507A1 AR P080102978 A ARP080102978 A AR P080102978A AR P080102978 A ARP080102978 A AR P080102978A AR 067507 A1 AR067507 A1 AR 067507A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- alkyl
- group
- amino
- aralkyl
- Prior art date
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- -1 trifluoromethylthiol Chemical group 0.000 abstract 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005111 carboxyalkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 102000015694 estrogen receptors Human genes 0.000 abstract 2
- 108010038795 estrogen receptors Proteins 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 210000004291 uterus Anatomy 0.000 abstract 2
- CPEONABTMRSIKA-UHFFFAOYSA-N 1,4$l^{2}-oxazinane Chemical compound C1COCC[N]1 CPEONABTMRSIKA-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000007984 Female Infertility Diseases 0.000 abstract 1
- 206010021928 Infertility female Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Su uso como ingredientes farmacéuticos activos que tienen una mayor afinidad in vitro por preparaciones de receptores de estrogeno de prostata de rata que por preparaciones de receptores de estrogeno de utero de rata, y que presentan una accion preferencial in vivo en el ovario en comparacion con el utero, con su produccion, su uso terapéutico, y con formas de administracion que contienen los nuevos compuestos. util para infertilidad femenina, reemplazo hormonal, artritis reumatoidea, lupus, enfermedad de Crohn, psoriasis, arteriosclerosis, endometriosis, cáncer de colon. Reivindicacion 1: Derivados de estra-1, 3, 5(10)-trieno 8beta-sustituidos CARACTERIZADOS porque son de formula general 1 donde los radicales R3, R8, R13, R16, así como R17 y R17', independientemente unos de otros, tienen el siguiente significado: R3 representa un átomo de hidrogeno o un grupo R18, donde R18 representa un radical C1-6-alquilo de cadena recta o cadena ramificada, saturado o insaturado, un grupo trifluorometilo, un radical arilo, heteroarilo o aralquilo opcionalmente sustituido con al menos un radical seleccionado independientemente entre metilo, etilo, trifluorometilo, pentafluoroetilo, trifluorometiltiol, metoxilo, etoxilo, nitro, ciano, halo, hidroxilo, amino, mono(C1-8-alquil) o di(C1-8-alquil)amino, donde ambos grupos alquilo son iguales o diferentes, di(aralquil)amino, donde ambos grupos aralquilo son iguales o diferentes, carboxilo, carboxialcoxilo, C1-20-acilo o C1-20-aciloxilo como sustituyentes; un radical acilo -C(=O)R19, donde R19 es una cadena recta o una cadena ramificada de un radical C1-C10-alquilo que está saturado o insaturado en hasta tres lugares, y que está parcialmente o completamente halogenado, o R18 representa un grupo R20SO2, donde R20 es un grupo R21R22N, donde R21 y R22, independientemente uno del otro, representan un átomo de hidrogeno, un radical C1-5-alquilo, un grupo -C(=O)R23, donde R23 representa un radical C1-10-alquilo no sustituido o sustituido, de cadena recta o cadena ramificada, que está saturado o insaturado en hasta tres lugares, y que está parcialmente o completamente halogenado, un grupo ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo o cicloheptilo, un radical C4-C15- cicloalquilalquilo con entre 3 y 7 átomos de carbono en la porcion de cicloalquilo, y con una porcion de alquilo de hasta 8 átomos de carbono, o un radical arilo, heteroarilo o aralquilo opcionalmente sustituido con al menos un radical seleccionado independientemente entre metilo, etilo, trifluorometilo, pentafluroetilo, trifluorometiltiol, metoxilo, etoxilo, nitro, ciano, halo, hidroxilo, amino, mono(C1-8-alquil) o di(C1-8-alquil) amino, donde ambos grupos alquilo son iguales o diferentes, di(aralquil)amino, donde ambos grupos aralquilo son iguales o diferentes, carboxilo, carboxialcoxilo, C1-20-acilo o C1-20-aciloxilo como sustituyentes; o junto con el átomo de N, forma un radical polimetilenimino con entre 4 y 6 átomos de carbono, o un radical morfolino, R8 es un radical alquenilo o alquinilo de cadena recta o cadena ramificada con entre 2 y 6 átomos de carbono, que opcionalmente puede estar parcialmente o completamente fluorado, R13 es un grupo metilo o un grupo etilo, R16 es un átomo de fluor en posicion alfa, R17 y R17', en cada caso independientemente uno del otros, son un átomo de hidrogeno y un grupo hidroxilo; o un átomo de hidrogeno y un grupo R18RO-, R20SO2- u OC(O)R23, donde en cada caso, R18, R20 y R23 tienen el significado que se indica bajo R3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07075600A EP2014672A1 (en) | 2007-07-12 | 2007-07-12 | 8-beta-substituted estratrienes as selectively active estrogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067507A1 true AR067507A1 (es) | 2009-10-14 |
Family
ID=38657613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102978A AR067507A1 (es) | 2007-07-12 | 2008-07-11 | Estratrienos 8-beta-sustituidos como estrogeno de accion selectiva |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20090029957A1 (es) |
| EP (2) | EP2014672A1 (es) |
| JP (1) | JP2010533152A (es) |
| KR (1) | KR20100037593A (es) |
| CN (1) | CN101687902B (es) |
| AR (1) | AR067507A1 (es) |
| AU (1) | AU2008274198A1 (es) |
| BR (1) | BRPI0814207A2 (es) |
| CA (1) | CA2692727A1 (es) |
| CL (1) | CL2008002027A1 (es) |
| CO (1) | CO6270230A2 (es) |
| CR (1) | CR11211A (es) |
| CU (1) | CU23885B1 (es) |
| CY (1) | CY1113351T1 (es) |
| DK (1) | DK2176282T3 (es) |
| DO (1) | DOP2010000017A (es) |
| EA (1) | EA017124B1 (es) |
| EC (1) | ECSP109872A (es) |
| ES (1) | ES2393942T3 (es) |
| HN (1) | HN2010000081A (es) |
| HR (1) | HRP20120952T1 (es) |
| MA (1) | MA31565B1 (es) |
| NZ (1) | NZ582490A (es) |
| PA (1) | PA8789401A1 (es) |
| PE (1) | PE20090825A1 (es) |
| PL (1) | PL2176282T3 (es) |
| PT (1) | PT2176282E (es) |
| RS (1) | RS52541B (es) |
| SI (1) | SI2176282T1 (es) |
| TN (1) | TN2010000007A1 (es) |
| TW (1) | TW200911824A (es) |
| UA (1) | UA99918C2 (es) |
| UY (1) | UY31220A1 (es) |
| WO (1) | WO2009007454A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014508784A (ja) * | 2011-03-25 | 2014-04-10 | ユニヴェルシテ ラヴァル | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
| CN110177610A (zh) * | 2016-06-24 | 2019-08-27 | K&N工程公司 | 复合式空气过滤器及其方法 |
| USD905747S1 (en) | 2018-04-09 | 2020-12-22 | Mitsubishi Electric Corporation | Display screen with animated graphical user interface |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1272505T3 (da) * | 2000-04-12 | 2005-11-07 | Schering Ag | 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater |
| DE10019167A1 (de) * | 2000-04-12 | 2001-10-18 | Schering Ag | Substituierte Estratriene als selektiv wirksame Estrogene |
-
2007
- 2007-07-12 EP EP07075600A patent/EP2014672A1/en not_active Ceased
-
2008
- 2008-07-11 TW TW097126522A patent/TW200911824A/zh unknown
- 2008-07-11 CL CL2008002027A patent/CL2008002027A1/es unknown
- 2008-07-11 CN CN200880024423XA patent/CN101687902B/zh not_active Expired - Fee Related
- 2008-07-11 SI SI200830826T patent/SI2176282T1/sl unknown
- 2008-07-11 PT PT08775031T patent/PT2176282E/pt unknown
- 2008-07-11 HR HRP20120952AT patent/HRP20120952T1/hr unknown
- 2008-07-11 PA PA20088789401A patent/PA8789401A1/es unknown
- 2008-07-11 EP EP08775031A patent/EP2176282B1/en active Active
- 2008-07-11 AR ARP080102978A patent/AR067507A1/es unknown
- 2008-07-11 JP JP2010515526A patent/JP2010533152A/ja not_active Ceased
- 2008-07-11 UA UAA201001369A patent/UA99918C2/ru unknown
- 2008-07-11 NZ NZ582490A patent/NZ582490A/en not_active IP Right Cessation
- 2008-07-11 UY UY31220A patent/UY31220A1/es not_active Application Discontinuation
- 2008-07-11 CA CA 2692727 patent/CA2692727A1/en not_active Abandoned
- 2008-07-11 RS RS20120516A patent/RS52541B/sr unknown
- 2008-07-11 ES ES08775031T patent/ES2393942T3/es active Active
- 2008-07-11 DK DK08775031.1T patent/DK2176282T3/da active
- 2008-07-11 PL PL08775031T patent/PL2176282T3/pl unknown
- 2008-07-11 KR KR1020107000527A patent/KR20100037593A/ko not_active Ceased
- 2008-07-11 EA EA201000097A patent/EA017124B1/ru not_active IP Right Cessation
- 2008-07-11 AU AU2008274198A patent/AU2008274198A1/en not_active Abandoned
- 2008-07-11 WO PCT/EP2008/059115 patent/WO2009007454A2/en not_active Ceased
- 2008-07-11 BR BRPI0814207-6A2A patent/BRPI0814207A2/pt not_active IP Right Cessation
- 2008-07-11 US US12/171,424 patent/US20090029957A1/en not_active Abandoned
- 2008-07-11 PE PE2008001165A patent/PE20090825A1/es not_active Application Discontinuation
-
2010
- 2010-01-07 MA MA32490A patent/MA31565B1/fr unknown
- 2010-01-07 TN TNP2010000007A patent/TN2010000007A1/fr unknown
- 2010-01-12 CO CO10002339A patent/CO6270230A2/es active IP Right Grant
- 2010-01-12 EC EC2010009872A patent/ECSP109872A/es unknown
- 2010-01-12 HN HN2010000081A patent/HN2010000081A/es unknown
- 2010-01-12 CU CU20100008A patent/CU23885B1/es not_active IP Right Cessation
- 2010-01-12 DO DO2010000017A patent/DOP2010000017A/es unknown
- 2010-01-12 CR CR11211A patent/CR11211A/es not_active Application Discontinuation
-
2012
- 2012-11-14 CY CY20121101099T patent/CY1113351T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1272505T3 (da) | 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater | |
| ES2671516T3 (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
| ES2665419T3 (es) | 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa | |
| ES2600703T3 (es) | Proceso para la producción de intermediarios de estetrol | |
| UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
| AR115694A1 (es) | Degradadores selectivos del receptor de estrógeno | |
| SV2001000020A (es) | Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb | |
| AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| AR067507A1 (es) | Estratrienos 8-beta-sustituidos como estrogeno de accion selectiva | |
| AR040188A1 (es) | Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva | |
| CR9627A (es) | Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof | |
| CR9598A (es) | Moduladores no esteroides de receptor de progesterona | |
| ES2312965T3 (es) | Sulfamatos de d-homoestra-1,3,5(10)-trien-3-il-2-sustituidos con efectos antitumoral. | |
| JP2010533152A5 (es) | ||
| AR066234A1 (es) | Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno | |
| UY29625A1 (es) | Uso de moduladores no esteroides de receptores de progesterona | |
| PE20090485A1 (es) | Proceso para la preparacion de 17-(3-hidroxipropil)-17-hidroxiesteroides | |
| DOP2010000198A (es) | Derivado de y-lactona del esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y medicamento que lo contiene | |
| CO6300840A2 (es) | Derivado y-lactona de esteroide de acido 15, 16-metilen-17-hidroxi-19-nor-21-carboxilico su uso y medicamentos que contienen tal derivado | |
| UY30815A1 (es) | Moduladores no esteroidales del receptor de progesterona | |
| GB928493A (en) | Steroid compounds | |
| PE20061161A1 (es) | Composicion farmaceutica que comprende un esteroide | |
| AR030018A1 (es) | Derivados de benzo(d)(1,3)oxazin-2-ona, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar medicamentos como moduladores receptores de progesterona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |